Takafumi Yamamoto
Overview
Explore the profile of Takafumi Yamamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, Tomonari T, et al.
Hepatol Int
. 2025 Feb;
PMID: 40019708
Background: This study aimed to investigate the changes in oncological resection status in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev) and the impact of conversion therapy...
2.
Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, et al.
Dig Liver Dis
. 2025 Jan;
PMID: 39828442
Background: Immune-related sclerosing cholangitis (irSC) induced by immune checkpoint inhibitors (ICIs) is relatively rare, and its clinical and pathological features are not well known. Aims: We aimed to compare the...
3.
A Proposal for a Simple Subclassification of Advanced Hepatocellular Carcinoma in Systemic Treatment
Imai N, Yamamoto T, Mizuno K, Yokoyama S, Yamamoto K, Ito T, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594752
Objectives: This study focused on the presence or absence of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma (HCC) and examined their impact on systemic treatment outcomes. Methods: We retrospectively...
4.
Yamamoto T, Abbas H, Cooray U, Yokoyama T, Tabuchi T
J Epidemiol
. 2024 Oct;
PMID: 39462542
BackgroundMultiple tobacco product (MTP) use is a public health concern due to their combined adverse health effects. MTP use may have increased since heated tobacco products (HTPs) became more prevalent...
5.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, et al.
PLoS One
. 2024 Sep;
19(9):e0311084.
PMID: 39321197
Durvalumab plus tremelimumab (Durva/Treme) combined immunotherapy is the first-line therapy recommended for unresectable hepatocellular carcinoma (HCC). Since sequential therapy is more effective in improving prognosis, tumor markers have been used...
6.
Yamamoto T, Ito T, Mizuno K, Yokoyama S, Yamamoto K, Imai N, et al.
Anticancer Res
. 2024 Aug;
44(9):4101-4111.
PMID: 39197910
Background/aim: The effects of body mass index (BMI) and body composition on the outcomes of systemic treatment for unresectable hepatocellular carcinoma (uHCC) remain unclear. Patients And Methods: In this retrospective...
7.
Kinugawa A, Yamamoto T, Kusama T, Takeuchi K, Osaka K
Nutrients
. 2024 Jul;
16(13).
PMID: 38999850
Eating out of home (EOH), with its diverse food options, can benefit those with difficulty preparing their meals, especially older adults. Oral health status may be a determinant of EOH,...
8.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, et al.
Oncol Lett
. 2024 Jul;
28(2):397.
PMID: 38979550
Although durvalumab plus tremelimumab (Dur/Tre) has been approved as first-line therapy for patients with unresectable hepatocellular carcinoma (u-HCC), its outcomes in real-world clinical practice are unclear. The present study aimed...
9.
Ito T, Mizuno K, Yamamoto T, Yasuda T, Yokoyama S, Yamamoto K, et al.
Hepatol Res
. 2024 Apr;
54(11):1060-1069.
PMID: 38571477
Aim: To detect immune-related adverse events (irAEs) early and treat them appropriately, our institute established an irAE-focused multidisciplinary toxicity team in cooperation with various departments. This study aimed to evaluate...
10.
Iwasaki M, Sato M, Takahashi D, Yamamoto T
J Prosthodont Res
. 2024 Mar;
68(4):643-649.
PMID: 38538330
Purpose: To determine whether the number of functional teeth, including the remaining natural teeth and prosthetically restored missing teeth, is associated with the dietary inflammatory index (DII), a quantitative measure...